Home/Filings/4/0001765581-25-000020
4//SEC Filing

Iannone Robert 4

Accession 0001765581-25-000020

CIK 0001232524other

Filed

Mar 2, 7:00 PM ET

Accepted

Mar 3, 8:22 PM ET

Size

6.9 KB

Accession

0001765581-25-000020

Insider Transaction Report

Form 4
Period: 2025-02-27
Iannone Robert
EVP, Global Head of R&D & CMO
Transactions
  • Award

    Ordinary Shares

    2025-02-27+17,71885,484 total
  • Award

    Ordinary Shares

    2025-02-27+8,85994,343 total
Footnotes (2)
  • [F1]These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2025, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.
  • [F2]These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units will vest in full on June 30, 2026.

Issuer

Jazz Pharmaceuticals plc

CIK 0001232524

Entity typeother

Related Parties

1
  • filerCIK 0001737329

Filing Metadata

Form type
4
Filed
Mar 2, 7:00 PM ET
Accepted
Mar 3, 8:22 PM ET
Size
6.9 KB